JW Pharmaceutial

2015.3.4 JW Holdings signs an MOU with Saudi Arabia's SPC to build an infusion plant

On March 4, 2015, JW Holdings signed a memorandum of understanding (MOU) for the construction of a $150 million infusion drug plant with Saudi Arabian pharmaceutical company SPC. The signing of this MOU paved the way for the domestic pharmaceutical industry to take a leap forward in that it builds a plant for the production of infusion solutions overseas using pure domestic technology, beyond general pharmaceutical exports.

2014.3 JW Creagen Approves CreaVax-HCC Phase 3 Clinical IND

In March 2014, CreaVax-HCC received approval for phase 3 clinical trials, paving the way for a breakthrough in the development of liver cancer treatments.reaVax-HCC phase 2 clinical results published in 2017 through Oncoimmunology confirmed that it significantly lowered the recurrence rate of liver cancer patients without significant side effects, demonstrating excellent technology worldwide.

2011.3.17 Acquired European CE certification for LED lightless lamps for the first time in Korea

On March 17, 2011, JW Medical acquired European CE certification for Honeylux LED, a LED light-free light.This is the first time that an LED shabby lamp developed with pure domestic technology has been officially certified in the European market. “The excellent quality and performance of Honeylux LED has been proven through CE certification.

2008.3.27 Choongwae Medical, relocated to Chungju factory

Choongwae Medical completed the Chungju plant on March 27, 2008, and dramatically improved the production infrastructure in the medical device field.The Chungju plant was designed as a facility that can meet various global certifications such as the US FDA, UL, Europe CE, and China CCC.